Christoph Rehfuess

Title: Christoph Rehfuess: Innovator in Vaccine Development

Introduction

Christoph Rehfuess is a notable inventor based in Munich, Germany. He has made significant contributions to the field of vaccine development, particularly in relation to HER2-related diseases. His innovative work has the potential to impact the treatment of various cancers.

Latest Patents

Rehfuess holds a patent for an "Anti-HER2 vaccine based upon AAV derived multimeric structures." This invention relates to parvovirus mutated structural proteins that include insertions of mimotopes of HER2. The patent encompasses compositions, multimeric structures, medicaments, and vaccines that utilize these proteins. Additionally, it covers nucleic acids, expression cassettes, constructs, vectors, and cells that incorporate the nucleic acids. The methods outlined in the patent aim to prepare the structural proteins and induce a B-cell response or treat HER2-related diseases.

Career Highlights

Christoph Rehfuess is associated with Medigene AG, a company focused on developing innovative immunotherapies for cancer treatment. His work at Medigene AG has positioned him as a key player in the advancement of therapeutic solutions in oncology.

Collaborations

Rehfuess collaborates with esteemed colleagues such as Uwe Michaelis and Erika Jensen-Jarolim. Their combined expertise enhances the research and development efforts within the company.

Conclusion

Christoph Rehfuess is a prominent inventor whose work in vaccine development is paving the way for new treatments for HER2-related diseases. His contributions to the field are invaluable and hold promise for future advancements in cancer therapy.